Novalis Biotech is an early stage venture capital investor in life sciences

We welcome innovative concepts in healthcare and aim to support their development already at the state of incorporation.

Our investment focus is “enabling technologies” in life sciences. We strongly believe in capital light platform technology and close interaction with customers already early in the life of the company. Focus areas are: innovative research and manufacturing tools, bioinformatics, genomics, diagnostics and digital health.

We focus on early-stage start-ups, from (pre-)seed stage to series A, and support their evolution by providing funding, sharing our professional and academic connections, and help to shape the business strategy in order to create value for all stakeholders.

News

Novalis Biotech invests in Rarity Bioscience’s ultra sensitive genomics technology

Novalis Biotech invests in Rarity Bioscience’s ultra sensitive genomics technology

Uppsala, Sweden, 06 Feb 2023 To further accelerate growth, Rarity Bioscience announces today a new strategic investment from Belgium based Novalis Biotech. The investment is...
Read more
C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

C-mo Medical Solutions extends seed investment round to €4.8 million to transform cough monitoring

C-mo Medical Solutions has announced an extension to its seed investment round. The round now totals €4.8 million and with the addition of Novalis Biotech...
Read more
Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients

Enzyre closes Series A financing round of EUR 12M to advance pioneering diagnostic technology platform for hemophilia patients

Funds will be used to accelerate development of proprietary ambulant diagnostic platform and to expand platform beyond hemophilia A.
Read more
Go to the News page

Novalis Portfolio


Rarity Bioscience

Rarity superRCA is an ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples like liquid biopsies. The format and flexibility of the technology platform – and read-out based on flow cytometry – makes it suitable for research as well as clinical application.

See more https://raritybioscience.com/

C-mo Medical Solutions

C-mo Medical Solutions is an award-winning digital health company with an innovative solution for the diagnosis and management of cough-incident medical conditions. The company’s mission is to unravel the clinical potential of cough assessment and solve the major unmet medical needs associated with the management of chronic cough.

Find out more at www.c-mo.solutions.

Carroucell

Carroucell is disrupting the biomanufacturing sector with its patented, innovative microcarrier and flexible process solution for customers. The microcarriers are based on a major innovation in the field of sol-gel process, which allows the production of bioactive microstructures not achievable by existing technologies.

In the bioreactor, cells can cling and multiply in “3D” which allows cultivation of a large quantity of cells in a restricted volume. Carroucell has a partnership with Etablissement Français du Sang (EFS), which enabled the validation of its microcarriers and facilitated first commercial orders. Carroucell was founded in 2016 by Tarek Fathallah.

For more information, visit www.carroucell.com.

Alithea Genomics

Alithea Genomics has developed a proprietary technology called Bulk RNA Barcoding and sequencing (BRB-seq), which enables the preparation of hundreds of RNA samples for sequencing in a single tube. By drastically decreasing the cost and time associated with library preparation for RNA sequencing, the BRB-seq technology enables for the first time the application of high-content and unbiased gene expression analysis to very large-scale projects, such as biobank functionalization and high-throughput drug screening.

Alithea Genomics was founded in May 2020 at the EPFL in Lausanne, Switzerland. More information can be found at www.alitheagenomics.com.

Trince

Trince is dedicated to advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells, both in vitro and ex vivo. The company’s LumiPore transfection platform, which is covered by a portfolio of pending patents, is used to deliver a wide variety of effector molecules (e.g. nucleic acids or proteins) into virtually any cell type, including hard-to-transfect cells such as immune cells for cell therapies. The technology ensures that this is done in a gentle manner, maximizing the therapeutic quality of the final cell product. www.trincebio.com

Modality.AI

Modality.AI, Inc. (“Modality”) has developed the first multimodal assessment platform to track the progression of neurological and psychiatric diseases through the analysis of facial musculature and phonetic enunciation, using a virtual agent to guide participants through standardized protocols. Modality’s rich, objective, and accurate audiovisual biomarkers expedite the development of therapies for diseases such as Parkinson’s, schizophrenia, depression, and autism, as well as the diagnosis and tracking of treatment efficacy at scale, as used by some of the leading clinical institutions in the world, including UCSF, MGH, NYU, Purdue, and the Charité.

Modality was founded by world-class AI experts with over 200 publications and issued patents and several successful exits. Modality is venture backed and based in San Francisco, CA.

Rheavita

RheaVita has developed a continuous, controlled freeze-drying technology that integrates all the traditional freeze-drying process steps into one continuous production line.

By spinning the glass vials during the freezing process, a thin layer of product coats the inner lining of the vial. Following drying, the final solid freeze-dried product is obtained. Compared to the traditional freeze-drying process, RheaVita’s approach has several advantages, including very fast product and process development with limited experimental efforts, avoiding scale-up issues, reducing cycle times, lower production costs, less clean room space requirements, improving quality assurance and improved and uniform product quality and process uniformity.

Grapheal

Grapheal develops wearable and disposable biosensors enabling continuous monitoring and in-field diagnosis. It empowers caregivers with an improved and individualized assessment tool for precision medicine. See more on www.grapheal.com

Enzyre

Enzyre, based in Nijmegen, The Netherlands, is a spin-out from Radboud University Medical Center, developing Enzypad, a near patient diagnostic and monitoring device initially focused on blood coagulation. Enzyre’s platform technology is unique as it requires just a small volume of blood and is able to measure up to twelve (12) biomarkers simultaneously without any laboratory infrastructure; at home, on the road or in a critical care setting. Enzyre’s proprietary technology is a small hand-held diagnostic tool using disease specific single use microfluidic cartridges with high sensitivity and specificity. It has broad applicability in several disease areas.

Cergentis

EXITED – Cergentis was acquired by Solvias

Cergentis is an innovative leader in genomics, provides kits and services based on its proprietary Targeted Locus Amplification (TLA) technology to leading diagnostic labs, research institutes and pharmaceutical companies worldwide.